• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Johns Hopkins Vasculitis Center

Show Search
Hide Search
  • About Our Center
    • Appointments and Directions
    • Meet Our Team
    • Support Our Center
  • What is Vasculitis?
    • Types of Vasculitis
    • Causes of Vasculitis
    • Symptoms of Vasculitis
    • Diagnosing Vasculitis
  • Vasculitis Treatments
    • Prednisone
    • Avacopan (Tavneos®)
    • Apremilast (Otezla®)
    • Azathioprine
    • Colchicine
    • Cyclophosphamide (Cytoxan)
    • Dapsone
    • Supplemental Immunoglobulin (IVIG/SCIG)
    • Leflunomide
    • Mepolizumab (Nucala®)
    • Methotrexate (MTX)
    • Mycophenolate
    • Rituximab
    • Sarilumab (Kevzara®)
    • TNF Inhibitors
    • Tocilizumab (Actemra®)
  • Vasculitis Research
  • Resources
Home / Search for "search.html/whatis/polyangiitis.html"

Search Results for: search.html/whatis/polyangiitis.html

Causes of Vasculitis

There are many different types of vasculitis, some with different causes than others.

Certain forms of vasculitis that can be due to infection where the microbe directly invades the vessel wall. Syphilis is one example of vasculitis that can be caused by infection in the blood vessel. Treating the infection is the main goal in managing this sort of vasculitis, which is not an autoimmune disease, but rather an infection.

Other infections can provoke the immune system into causing damage in blood vessels. Here, the infection is the trigger, but the immune system is the cause of the vascular damage. Viral hepatitis (B and C) are examples of this sort: some patients with Hepatitis B may develop polyarteritis nodosa, while some patients with Hepatitis C may develop cryoglobulinemic vasculitis.

Other types of vasculitis may be due to an ‘allergic‘-type reaction to medications. For example, certain blood pressure medications (hydralazine) or thyroid medications (propylthiouracil) can trigger ANCA associated vasculitis in some patients. Cocaine is an illicit drug that is linked to vasculitis and vascular damage.

However, the causes of most vasculitides are currently unknown. While we can identify some risk factors (such as older age in giant cell arteritis), we do not know the specific causes of these diseases. These forms of vasculitis of unknown cause are considered autoimmune diseases.

Under normal circumstances, our immune system serves to defend us from infection and other threats, such as cancers. In autoimmune diseases, the immune system generates a response not against a foreign threat, but against normal “self” tissues. This abnormal immune response against “self” tissues can result in a wide array of autoimmune diseases, including relatively common diseases (such as psoriasis or thyroid disease) as well as rare conditions (such as vasculitis).

In most cases, autoimmune diseases are believed to be due to an abnormal immune response that is generated in a susceptible person, and eventually leads to a cycle of ongoing inflammation in otherwise normal tissues where no infection or other identifiable threat is present. Some interaction between the immune system and the environment is thought necessary for this to occur, and a person’s genetic background likely places some individuals at higher risk than others.

A better understanding of the specific causes of these diseases would lead to improved means of diagnosing, treating, and even preventing these conditions. Uncovering the causes of vasculitis is a major goal of vasculitis research.

While we may not know the specific causes of the vasculitidies, we do have a basic understanding of the way that the immune system causes organ damage in these conditions. In all forms of vasculitis, activation of the immune system leads to the deposition of inflammatory cells and proteins in the walls of blood vessels. As this inflammation in blood vessels continues, the vessels become damaged and no longer serve their normal function of delivering blood to the organs that they supply. Consequently, the tissues downstream of these inflamed vessels are starved of oxygen and nutrients needed for normal function. At a basic level, this is a process similar to what occurs in a heart attack or a stroke – but instead of the cholesterol plaque that blocks a coronary artery in a heart attack, the immune system is responsible for blockage of blood vessels in vasculitis.

All information contained within the Johns Hopkins Vasculitis Center website is intended for educational purposes only. Visitors are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.

Mepolizumab (Nucala®)

What is mepolizumab?

Mepolizumab is a monoclonal antibody approved for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA).

How does mepolizumab work?

Mepolizumab blocks IL-5 – a molecule involved in the maturation and activation of eosinophils.

Eosinophils are a type of white blood cell associated with allergic reactions. Eosinophils are implicated in the inflammation present in EGPA, and are often found in the tissues affected by this form of vasculitis.

By blocking IL-5, mepolizumab inhibits the accumulation of eosinophils in the tissues affected by EGPA.

How is mepolizumab given?

Mepolizumab is given as a self-injection at a dose of 300 mg every 4 weeks for EGPA.

Side effects:

Eosinophils do not play as important a role in the normal immune response to typical infections as do other white blood cells, such as neutrophils or lymphocytes. Consequently, mepolizumab is not associated with the same sorts of infections that are the major risk encountered with other immunosuppressant medications.

All immunosuppressants require regular monitoring in the form of blood tests, in-person assessments, and vigilance for signs of infection.

  • « Go to Previous Page
  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to page 4

Primary Sidebar


donate to the Johns Hopkins Vasculitis Center

All information contained within the Johns Hopkins Vasculitis Center website is intended for educational purposes only. Visitors are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.

Footer

Johns Hopkins Rheumatology

  • Johns Hopkins Rheumatology
  • Johns Hopkins Arthritis Center
  • Johns Hopkins Lupus Center
  • Johns Hopkins Lyme Disease Research Center
  • Johns Hopkins Myositis Center
  • Johns Hopkins Scleroderma Center
  • Johns Hopkins Sjögren’s Syndrome Center

Connect With Us

  • Facebook
  • Twitter
  • YouTube
U.S. News and World Report Rankings Badge

Johns Hopkins Medicine Johns Hopkins Medicine logo
Language Assistance Available:
  • Español
  • American Sign Language
  • עִברִי
  • אידיש
  • አማርኛ
  • 繁體中文
  • Français
  • Tagalog
  • Русский
  • Português
  • Italiano
  • Tiếng Việt
  • Ɓàsɔ́ɔ̀-wùɖù-po-nyɔ̀
  • Igbo asusu
  • èdè Yorùbá
  • বাংলা
  • 日本語
  • 한국어
  • Kreyòl Ayisyen
  • العربية
  • Deutsch
  • Polski
  • Ελληνικά
  • ગુજરાતી
  • ภาษาไทย
  • اُردُو
  • فارسی
  • हिंदी
  • Deitsch
  • ខ្មែរ
  • မြန်မာ
Contact & Privacy Information
Price Transparency
Notice of Privacy Practices Privacy Statement
Terms & Conditions of Use Non-Discrimination Notice
Manage Cookie Preferences
Copyright © 2025 Johns Hopkins Rheumatology